> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Syndax Revuforj Sales Climb 90% To $60.7 Million As Leukemia Drugmaker Swaps CFOs
- URL: https://www.bullished.co/syndax-revuforj-sales-climb-90-to-60-7-million-as-leukemia-drugmaker-swaps-cfos-7c980551/
- Published: 2026-11-02T22:27:01.000Z
- Updated: 2026-11-02T22:27:01.000Z
- Description: Third-quarter revenue rose 82% to $83.3 million, the net loss narrowed, and Aaron Ondrey replaces retiring CFO Keith Goldan on November 9.
- Author: Matteo Parrino
- Tags: Earnings, SNDX, Industry: Healthcare

[Syndax Pharmaceuticals](https://www.bullished.co/tag/sndx/), a commercial-stage company that develops cancer therapies, reported third-quarter revenue of [$83.3 million](https://www.sec.gov/Archives/edgar/data/0001395937/000119312526443613/sndx-20261102.htm?ref=bullished.co), up 82% from a year earlier, in an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Monday. The company also said CFO Keith Goldan will retire and Aaron Ondrey will take over.

## Two drugs, $83.3 million

Revuforj, the oral leukemia drug, brought in [$60.7 million](https://www.sec.gov/Archives/edgar/data/0001395937/000119312526443613/sndx-ex99%5F1.htm?ref=bullished.co) of net revenue, up 90% from the third quarter of 2025 and 11% from the second quarter. New patients rose about 20% and total prescriptions about 13% from the prior quarter.

The other $22.6 million was collaboration revenue from Niktimvo, which Syndax co-commercializes with Incyte. That is Syndax's 50% share of Niktimvo's net commercial profit, which is net revenue minus cost of sales and commercial expenses. Incyte reported Niktimvo net revenue of $67.4 million, up 47% from a year earlier.

CEO Michael Metzger said a growing number of relapsed or refractory patients are proceeding to a stem cell transplant after Revuforj and then resuming therapy. Claims data indicate about 50% of KMT2A-rearranged patients get a transplant, and about 60% of them resume therapy afterward.

## A narrower loss, rising research bill

The net loss attributable to common stockholders narrowed to $49.4 million, or $0.55 per share, from $60.7 million, or $0.70 per share, a year earlier. Research spending rose to $67.5 million from $56.3 million, which the company attributed mainly to frontline trials of revumenib, Revuforj's active ingredient, in newly diagnosed acute myeloid leukemia. Selling, general and administrative costs fell to $43.7 million from $44.9 million.

Syndax held $551.1 million in cash and investments at September 30 and still expects 2026 research plus selling and administrative expenses of about $400 million, excluding $50 million of estimated non-cash stock compensation.

In October, the company said a mid-stage trial of Niktimvo in idiopathic pulmonary fibrosis missed its main goal, and it does not plan further development in that disease.

## Ondrey steps in November 9

Goldan retires as CFO effective November 9 and will then serve as an advisor for an interim period. Ondrey joins that day; he was most recently CFO of Beren Therapeutics, a private company, and earlier held the CFO job at Rocket Pharmaceuticals and Mirati Therapeutics.

His contract sets a $543,000 base salary, a target bonus of 45% of salary and an option on 270,000 shares priced at the November 9 close.

Syndax expects new Revuforj frontline, post-transplant and real-world data in the fourth quarter.

Syndax said it will present those fourth-quarter data at upcoming medical meetings, including ASH.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Syndax Pharmaceuticals Inc (SNDX)](https://www.sec.gov/Archives/edgar/data/0001395937/000119312526443613/sndx-20261102.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit sndx-ex99\_1.htm — Syndax Pharmaceuticals Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001395937/000119312526443613/sndx-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit sndx-ex99\_2.htm — Syndax Pharmaceuticals Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001395937/000119312526443613/sndx-ex99%5F2.htm?ref=bullished.co) — SEC EDGAR
- [Syndax Reports Third Quarter 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/11/02/3393699/0/en/syndax-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com
- [Syndax Announces CFO Transition – Aaron A. Ondrey Appointed](https://www.globenewswire.com/news-release/2026/11/02/3393696/0/en/syndax-announces-cfo-transition-aaron-a-ondrey-appointed-chief-financial-officer.html?ref=bullished.co) — globenewswire.com
- [Syndax Announces Participation in November Investor](https://rss.globenewswire.com/news-release/2026/10/30/3392139/0/en/syndax-announces-participation-in-november-investor-conferences.html?ref=bullished.co) — rss.globenewswire.com

### More on Syndax Pharmaceuticals

- [Syndax Revenue Jumps 82% To $83.3 Million, Yet Stockholders' Equity Slips Into A $17.2 Million Deficit](https://www.bullished.co/syndax-revenue-jumps-82-to-83-3-million-yet-stockholders-equity-slips-into-a-17-2-million-afdb1120/)

[All Syndax Pharmaceuticals (SNDX) coverage →](https://www.bullished.co/tag/sndx/)